tbuckley/cabot-search huggingface dataset:
Comprehensive management of vulvovaginal cancers
Authors: Angélica Nogueira‐Rodrigues, Maaike H. M. Oonk, Domenica Lorusso, Brian Slomovitz, Mario M. Leitão, Glauco Baiocchi
Journal: CA A Cancer Journal for Clinicians (2025)

Abstract Vulvar and vaginal cancers represent rare malignancies, with an incidence of 2.7 per 100,000 women for vulvar cancer, predominantly affecting women older than 60 years, although rising rates are observed in younger demographics. Approximately 90% of vulvar cancers are squamous cell carcinoma and frequently are associated with human papillomavirus (HPV) infection. Vaginal cancer, constituting less than 1% of all female cancers, similarly exhibit HPV‐related trends. This review delineates the etiology, histopathology, and treatment strategies for carcinomas and vulvovaginal melanomas and sarcomas. Surgical intervention remains the primary treatment modality for vulvar cancer, involving tumor resection and inguinofemoral lymph node staging. For locally advanced vulvar carcinoma, chemoradiation is advised when exenterative surgery would be indicated. Recurrence rates within 2 years after diagnosis range from 12% to 37%. Unfortunately, systemic treatments for recurrent or metastatic disease are limited, with 5‐year survival rates at approximately 20%. Current evidence primarily derives from retrospective studies or small phase 2 trials or otherwise is extrapolated from the treatment of cervical cancer. Enrollment in clinical trials is strongly advocated, along with prompt access to best supportive care to mitigate the effect of locoregional progression on quality of life. Moreover, the psychosocial implications of treatment on body image and sexuality necessitate careful consideration. Future HPV vaccination initiatives may reduce cancer incidence, although significant effects of such vaccination will manifest over decades, underscoring the urgent need to enhance treatment efficacy and minimize morbidity in vulvar and vaginal cancers.
Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the <scp>FINEARTS</scp>‐<scp>HF</scp> trial
Authors: Misato Chimura, Mingming Yang, Alasdair D. Henderson, Pardeep S. Jhund, Kieran F. Docherty, Brian L. Claggett, Akshay S. Desai, Gerasimos Filippatos, Grzegorz Gajos, Katharina Mueller, Andrea Glasauer, Katja Rohwedder, Prabhakar Viswanathan, Carolyn S.P. Lam, Naoki Sato, Michele Senni, Adriaan A. Voors, Faiez Zannad, Mehmet B. Yilmaz, Bertram Pitt, Muthiah Vaduganathan, Scott D. Solomon, John J.V. McMurray
Journal: European Journal of Heart Failure (2025)
Disease-modifying antirheumatic drug–free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study
Authors: Selinde V J Snoeck Henkemans, Marijn Vis, Gonul Hazal Koc, Jolanda J Luime, Marc R Kok, Ilja Tchetverikov, Karen Visser, Lindy-Anne Korswagen, Jessica Bijsterbosch, Maikel van Oosterhout, Paul Baudoin, Jos H van der Kaap, Annette H M van der Helm-van Mil, Pascal H P de Jong
Journal: Annals of the Rheumatic Diseases (2025)

According to current management guidelines for psoriatic arthritis (PsA) tapering of disease-modifying antirheumatic drugs (DMARDs) can be considered. However, limited data are available on complete DMARD cessation, also known as disease-modifying antirheumatic drug-free remission (DFR). Therefore, our aim was to investigate whether DFR is achievable and sustainable in PsA and to evaluate possible predictors for sustained disease-modifying antirheumatic drug-free remission (SDFR). From the Dutch southwest Early Psoriatic Arthritis cohort, all newly diagnosed patients with oligoarticular/polyarticular PsA who were treated with DMARDs were included (n = 451). Prevalence of (S)DFR and flare rates (early and late) were described. DFR was defined as the absence of clinical synovitis for ≥3 months after DMARD cessation, while for SDFR, a period of >1 year was used. Early and late flares were defined as restarting DMARD treatment ≤1 and >1 year after DMARD cessation, respectively. Subsequently, possible predictors for true SDFR, that is, SDFR without flaring were explored. After a median of 5.1 years (IQR, 3.0-7.3 years), 22% of patients with PsA had reached DFR, and after reaching DFR, 4.7% had an early flare. Thus, SDFR was achieved in 14.4% of patients with PsA; 5.3% experienced a late flare, which occurred a median of 1.7 years (IQR, 1.4-2.8 years) after DMARD cessation. Eventually, 9.1% of patients reached true SDFR. Low baseline Disease Activity Index in Psoriatic Arthritis and never using biological or targeted synthetic DMARDs were independent predictors for true SDFR. At the time of true SDFR, the Health Assessment Questionnaire was similar to the general population (median, 0.12; IQR, 0-0.75). DFR is attainable in oligoarticular/polyarticular PsA and is sustainable in 9% of patients. However, the subgroup of patients with PsA with high disease activity at baseline and who require biological or targeted synthetic DMARDs do not achieve true SDFR. To our knowledge, this is the first study to demonstrate that chronicity can potentially be influenced in a proportion of patients with PsA.
Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The <scp>FINEARTS</scp>‐<scp>HF</scp> trial
Authors: Jonathan W. Cunningham, Brian L. Claggett, Muthiah Vaduganathan, Akshay S. Desai, Pardeep S. Jhund, Carolyn S.P. Lam, Michele Senni, Sanjiv Shah, Adriaan Voors, Faiez Zannad, Bertram Pitt, Flaviana Amarante, James Lay‐Flurrie, Katja Rohwedder, Laura Goea, Mario Berger, John J.V. McMurray, Scott D. Solomon
Journal: European Journal of Heart Failure (2025)
Frameworks to support evidence-informed decision-making in public health and infectious disease prevention and control: a scoping review
Authors: Yang Song, Javier Bracchiglione, Jose F Meneses-Echávez, Helena de Carvalho Gomes, Barbara Albiger, Ivan Solà, David Rigau, Pablo Alonso-Coello
Journal: Eurosurveillance (2025)

Background Evidence-informed public health decision-making (EIDM) is a complex process that must consider multiple factors. Aim We aimed to identify and describe existing frameworks supporting evidence-informed public health decision-making and their application to infectious disease. Methods We conducted a scoping review to describe current EIDM framework use in public health. We included decision-making frameworks in public health and examples of their use in infectious diseases. We searched MEDLINE and Health Systems Evidence from inception to December 2022. We also hand searched websites of relevant organisations and conducted a forward citation search of the included frameworks. Two reviewers selected studies independently, one reviewer extracted data and one cross-checked for accuracy. We presented the results narratively. Results We included 15 frameworks. Seven had a generic scope and eight were focused on specific topics (immunisation, COVID-19 or other, non-infectious diseases). From the included frameworks, we identified a total of 18 criteria with each framework assessing a median of eight, the most frequent being ‘desirable effects’, ‘resources considerations’ and ‘feasibility’. We identified infectious disease examples for four frameworks: ‘Grading of Recommendations, Assessment, Development, and Evaluation’ (GRADE), WHO-INTEGRATe Evidence (WHO-INTEGRATE), ‘Ethics, Equity, Feasibility, and Acceptability’ (EEFA) and ‘Community Preventive Services Task Force’ (CPSTF) evidence-to-decision frameworks. Conclusion Although several EIDM frameworks exist for public health decision-making, most have not been widely applied to infectious diseases. Current EIDM frameworks inconsistently address factors for public health decision-making. Further application and evaluation, and possibly adaptation of existing frameworks, is required to optimise decision-making in public health and infectious diseases.
Air and surface sampling for clade Ib monkeypox virus in United Kingdom hospitals, 2024 to 2025
Authors: Barry Atkinson, Susan Gould, Ian Nicholls, Khanzadi Nazneen Manzoor, Jack Smith, Andrew J. Hindle, Anne J. Tunbridge, Joby Cole, Paul Collini, Alejandra Alonso, Geraldine O’Hara, Cecilia Tuudah, Jonathan A. Otter, Berkin Hack, Caroline Taylor, Thomas Pottage, Tom Fletcher, Jake Dunning
Journal: Eurosurveillance (2025)

Air and surface sampling was performed in isolation rooms of seven patients with clade Ib mpox admitted to high consequence infectious disease centres in the United Kingdom. We detected monkeypox virus (MPXV) DNA in 66/90 surfaces samples and 1/14 air samples; replication competent MPXV was identified in 4/21 surface samples selected for viral isolation. These findings demonstrate that viable clade Ib MPXV contamination can occur during treatment of clade Ib mpox patients reinforcing the importance of infection prevention and control measures.
Human infections with Eurasian avian-like swine influenza virus detected by coincidence via routine respiratory surveillance systems, the Netherlands, 2020 to 2023
Authors: Dirk Eggink, Annelies Kroneman, Jozef Dingemans, Gabriel Goderski, Sharon van den Brink, Mariam Bagheri, Pascal Lexmond, Mark Pronk, Erhard van der Vries, Evelien Germeraad, Diederik Brandwagt, Manon Houben, Mariëtte van Hooiveld, Joke van der Giessen, Rianne van Gageldonk-Lafeber, Ron Fouchier, Adam Meijer
Journal: Eurosurveillance (2025)

Background Zoonotic influenza, including infections with avian and swine influenza A viruses (swIAV), is a notifiable disease in the Netherlands. Human cases infected with swIAV have previously been rarely detected in the Netherlands. Aim We aimed to describe detection and characterisation of Eurasian avian-like swIAV infections in humans in the Netherlands 2020–2023. Methods The Dutch National Influenza Center coordinates different activities to monitor respiratory infections and circulating human influenza viruses. This monitoring includes sentinel surveillance in general practitioner practices, community participatory surveillance and characterisation of influenza viruses received from diagnostic laboratories. A subset of the specimens positive for influenza A virus from the monitoring activities are sent for further characterisation. We characterised swIAV from human patients using whole genome sequencing, tested the viruses for antiviral susceptibility and in haemagglutination inhibition assays for antigenic characterisation and compared them with previous detections from humans and pigs. Results Avian-like swine influenza virus was detected in three persons presenting with mild respiratory symptoms, and all recovered fully. Only one patient had close contact with pigs shortly before the start of symptoms. Sequence analyses of the viruses showed clustering with swAIV from pigs in a recently initiated surveillance system on pig farms. Conclusions These human cases show that swIAV viruses with zoonotic potential are enzootic in the Netherlands. Finding them by coincidence suggests human infections might occur more frequently than noticed.
Development‐Inspired Biomimetic Cell‐Niche Coaggregates Safeguard Tooth Stem Cell‐Based Functional Tissue Regeneration
Authors: Xiao‐Hui Zhang, Yi‐De He, Hao Wang, Yuan Cao, Si‐Qi Ying, Jia‐Ning Liu, Xiao Lei, Lu Liu, Xin‐Yue Cai, Shi‐Han Mu, Kai‐Chao Zhang, Yuan Yuan, Yi‐Han Liu, Hao‐Kun Xu, Ji Chen, Jian‐Fei Liang, Yan Jin, Fang Jin, Bing‐Dong Sui, Chen‐Xi Zheng
Journal: Advanced Healthcare Materials (2025)

Abstract Harnessing natural developmental programs to repair and replace damaged organs represents promising approaches in regenerative medicine. However, effective strategies are still lacking for tissue regeneration in complicated conditions, such as the periodontal bone defect. Here, human dental follicle stem cells (hDFSCs) and their aggregates (hDFSCA) are cultured and characterized, which are formed based on the inherent property of these stem cells self‐assembly into compact spheroid‐like structures, mimicking mesenchymal condensation in development. A periodontal tissue‐specific microenvironment simulation material is then established, human decellularized alveolar bone matrix particles (hDABMPs), which possess favorable physicochemical and biological properties for regenerative use. hDFSCs co‐cultured with hDABMPs exhibit improved cell function, and hDFSCA‐hDABMP co‐aggregates are subsequently constructed, which activate the developmental gene expression in hDFSCA and initiate hypoxic adaptation mechanisms for tissue regeneration. Indeed, hDFSCA‐hDABMP co‐aggregates significantly promote regeneration after implantation in alveolar bone defects with good biosafety. Interestingly, during the early stages of implantation, hDABMPs enhance hDFSC survival and expansion, thereby providing a sufficient source of cells for tissue regeneration. Collectively, this study reveals a development‐inspired, engineered cell‐niche co‐aggregation strategy for enhancing CA therapeutic potential by simulating tissue‐specific microenvironments, offering novel insights for functional tissue regeneration.
Users’ experience of frameworks to support evidence-informed decision-making in public health: a scoping review
Authors: Javier Bracchiglione, Yang Song, Jose F Meneses-Echávez, Helena de Carvalho Gomes, Barbara Albiger, Ivan Solà, David Rigau, Pablo Alonso-Coello
Journal: Eurosurveillance (2025)

Background Evidence-informed decision-making in public health (PH) is a complex process requiring the consideration of multiple perspectives and contextual factors. Evidence-to-decision (EtD) frameworks are structured approaches aiming to improve decision-making by considering critical criteria, but users’ experience has not been systematically synthesised. Aim We aim to summarise users’ experiences of EtD frameworks used for PH. Methods As part of a broader scoping review, we identified 15 EtD frameworks for PH decision-making. We searched MEDLINE and Health Systems Evidence, conducted a hand search and citation search strategy for documents reporting users’ experience of EtD frameworks and surveyed key stakeholders. We conducted a descriptive thematic synthesis, identifying main barriers and facilitators, complementing with surveys to relevant stakeholders. Results We identified 12 studies reporting users’ experience of two EtD frameworks: Grading of Recommendations Assessment, Development and Evaluation (n = 9) and World Health Organization INTEGRATe Evidence (n = 3). Both were perceived as structured approaches that enhanced the use of evidence while including contextual factors and facilitating consensus-building processes. Main barriers were lack of high-quality evidence for the effectiveness of PH interventions, limitations of the terminology or unclear boundaries between specific criteria, perceptions of missing criteria and the need for more guidance. Survey responses (n = 13) were consistent with these findings. Conclusion Users of the two frameworks had an overall positive perception of the approaches, but several barriers remain. These experiences may change over time as the frameworks evolve. There is an evidence gap regarding users’ experience for other EtD frameworks.
Integrated Iontronic FMG‐sEMG Sensing for Decoding Muscle Activation Mechanisms and Force Assessment
Authors: Peikai Zou, Junhan Wang, Xian Zhao, Xigong Zhang, Kehan Hua, Yejun Zha, Ruya Li, Yubo Fan
Journal: Advanced Healthcare Materials (2025)

Abstract Muscle activity generates both physiological electrical and mechanical signals, the monitoring of which is crucial in rehabilitation and sports medicine, underpinning effective diagnosis, treatment, and rehabilitation processes. Advances in flexible electronics enable force myography (FMG) and surface electromyography (sEMG) signals for muscle activation monitoring, but the multi‐sensor integration and physiological mechanisms underlying FMG signals remain poorly studied, limiting the accuracy of muscle function assessments and underutilizes the high sensitivity of the flexible sensors. This study introduces a novel thin‐film iontronic force‐electromyography (iFEMG) sensor, integrating a high‐sensitivity iontronic pressure sensor and sEMG electrodes for high‐fidelity muscle physiological signal acquisition. Based on ultrasound imaging and statistical analysis, the relationship between muscle force, muscle geometric features, and FMG signals is established, providing evidence for elucidating the physiological mechanisms of FMG signals. Based on these findings, an effective and highly adaptable method is proposed for precise muscle force prediction. The iFEMG system is successfully applied to assess motor nerve and muscle function in patients, demonstrating its clinical utility. This system holds significant potential for broader applications, such as rehabilitation training and early diagnosis of musculoskeletal disorders, paving the way for advanced personalized healthcare solutions.
Ultrasmall Nanoparticles Mitigate Tau Hyperphosphorylation to Restore Synaptic Integrity and Boost Cognitive Function in Alzheimer's Disease
Authors: Hanbing Xu, Gang Wang, Zhilin Jiang, Yaobao Han, Weiming Zhao, Hao Zhang, Hong Liu, Huayue Liu, Zhen Li, Fuhai Ji
Journal: Advanced Healthcare Materials (2025)

Abstract Tau hyperphosphorylation represents a critical pathological hallmark of Alzheimer's disease (AD), a prevalent neurodegenerative disorder characterized by progressive cognitive decline. The ubiquitin‐specific proteases 14 (USP14) impairs proteasomal function and accelerates hyperphosphorylated Tau accumulation, making it an attractive therapeutic target for modulating the ubiquitin‐proteasome pathway in AD treatment. In this study, it is reported that wogonoside‐functionalized ultrasmall Cu 2‐x Se nanoparticles (CSPW NPs) significantly reduce hyperphosphorylated Tau accumulation and alleviate AD symptoms. The therapeutic mechanism involves activation of the ubiquitin‐proteasome pathway through USP14 inhibition by CSPW NPs, thereby preventing hyperphosphorylated Tau accumulation. Furthermore, after cell membrane coating (CSPW@CM NPs), these nanoparticles efficiently cross the blood–brain barrier with focused ultrasound assistance and accumulate in the brain to target neurons. Within neurons, they inhibit USP14, reduce phosphorylated Tau deposition, enhance microtubule stability, mitigate synaptic loss, restore synaptic integrity, and ultimately alleviate cognitive dysfunction in AD mice. The findings highlight the substantial potential of USP14 modulation for mitigating Tau hyperphosphorylation in the treatment of AD and related tauopathies.
Intestinal and esophageal microbiota in esophageal cancer development and treatment
Authors: Yuta Baba, Kohei Tajima, Kiyoshi Yoshimura
Journal: Gut Microbes (2025)

Esophageal cancer (EC) is the eleventh most commonly diagnosed cancer, and its prognosis remains poor. Several challenges remain for improving the clinical outcomes of EC, and improving technologies for early detection, diversifying treatment options, and advancing personalized treatment are essential. Alterations in the intestinal and esophageal microbiota are associated with the pathogenesis and progression of EC; for instance, Fusobacterium nucleatum is important in the pathogenesis and progression of esophageal squamous cell carcinoma. Therefore, a novel diagnostic biomarker may be identified using the intestinal microbiota. Furthermore, targeting the intestinal and esophageal microbiota may help in the early detection of EC, use of a novel prognostic biomarker, and even the detection of a therapeutic target, resulting in a more individualized therapeutic approach for EC. In this review, we summarize the clinical research focused on the intestinal and esophageal microbiota in EC development and its treatment, and discuss the challenges in the clinical application of intestinal and esophageal microbiota.
Interventions targeting the gut microbiota and their possible effect on gastrointestinal and neurobehavioral symptoms in autism spectrum disorder
Authors: Evelyn Takyi, Khemlal Nirmalkar, James Adams, Rosa Krajmalnik-Brown
Journal: Gut Microbes (2025)

Autism spectrum disorder (ASD) is a developmental disorder that is characterized by deficits in social communication and restricted, repetitive, and stereotyped behaviors. In addition to neurobehavioral symptoms, children with ASD often have gastrointestinal symptoms (e.g. constipation, diarrhea, gas, abdominal pain, reflux). Several studies have proposed the role of gut microbiota and metabolic disorders in gastrointestinal symptoms and neurodevelopmental dysfunction in ASD patients; these results offer promising avenues for novel treatments of this disorder. Interventions targeting the gut microbiota - such as fecal microbiota transplant (FMT), microbiota transplant therapy (MTT), probiotics, prebiotics, synbiotics, antibiotics, antifungals, and diet - promise to improve gut health and can potentially improve neurological symptoms. The modulation of the gut microbiota using MTT in ASD has shown beneficial and long-term effects on GI symptoms and core symptoms of autism. Also, the modulation of the gut microbiota to resemble that of typically developing individuals seems to be the most promising intervention. As most of the studies carried out with MTT are open-label studies, more extensive double-blinded randomized control trials are needed to confirm the efficacy of MTT as a therapeutic option for ASD. This review examines the current clinical research evidence for the use of interventions that target the microbiome - such as antibiotics, antifungals, probiotics/prebiotics, synbiotics, and MTT - and their effectiveness in changing the gut microbiota and improving gastrointestinal and neurobehavioral symptoms in ASD.
Mechanically and Chemically Defined PEG Hydrogels Improve Reproducibility in Human Cardioid Development
Authors: Yuanhui Song, Michael Seitz, Andrew Kowalczewski, Nhu Y Mai, Era Jain, Huaxiao Yang, Zhen Ma
Journal: Advanced Healthcare Materials (2025)

Abstract Cardioids are 3D self‐organized heart organoids directly derived from induced pluripotent stem cells (hiPSCs) aggregates. The growth and culture of cardioids is either conducted in suspension culture or heavily relies on Matrigel encapsulation. Despite the significant advancements in cardioid technology, reproducibility remains a major challenge, limiting their widespread use in both basic research and translational applications. Here, for the first time, we employed synthetic, matrix metalloproteinase (MMP)‐degradable polyethylene glycol (PEG)‐based hydrogels to define the effect of mechanical and biochemical cues on cardioid development. Successful cardiac differentiation is demonstrated in all the hydrogel conditions, while cardioid cultured in optimized PEG hydrogel (3 wt.% PEG‐2mM RGD) underwent similar morphological development and comparable tissue functions to those cultured in Matrigel. Matrix stiffness and cell adhesion motif play a critical role in cardioid development, nascent chamber formation, contractile physiology, and endothelial cell gene enrichment. More importantly, synthetic hydrogel improved the reproducibility in cardioid properties compared to traditional suspension culture and Matrigel encapsulation. Therefore, PEG‐based hydrogel has the potential to be used as an alternative to Matrigel for human cardioid culture in a variety of clinical applications including cell therapy and tissue engineering.